Brief: Orphazyme Updates On NDA Resubmission For Arimoclomol In The United States

Strategic Partners A/S

11/02/2022 06:57

Feb 11 (Reuters) - Orphazyme A/S  ORPHA.CO :
    * ORPHAZYME PROVIDES UPDATE FOR PLANNED NDA RESUBMISSION FOR
ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN-PICK DISEASE TYPE C IN
THE UNITED STATES
    * PLANS TO REQUEST A TYPE C MEETING IN Q2 2022
    * AIMS TO RESUBMIT NDA DURING H2 2022
    * REQUESTING A TYPE C MEETING IS NEXT STEP IN ESTABLISHING A
POTENTIAL PATH TO RESUBMISSION OF OUR NDA TO FDA

Source text for Eikon:  ID:nGNE2cMRgG 
Further company coverage:  ORPHA.CO 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))